Eastern equine encephalitis virus structural polyprotein (EEEV structural protein) (EEEV structural protein)

The Eastern equine encephalitis virus (EEEV) structural polyprotein is a precursor protein that is cleaved into five individual components: the capsid protein (C), and the envelope glycoproteins E3, E2, 6K, and E1 [UniProt P08490]. These proteins are essential for the assembly of the viral particle and the infection of host cells [Hundie et al., 2022]. The E2 glycoprotein is primarily responsible for receptor binding and attachment to the host cell surface, while the E1 glycoprotein mediates the pH-dependent fusion of the viral envelope with the endosomal membrane [Adams et al., 2021]. Because these proteins are exposed on the surface of the virion, they are the primary targets for the host immune response and the focus of therapeutic development [Hundie et al., 2022]. Current research focuses on developing neutralizing monoclonal antibodies, such as EEEV-143 and EEEV-33, which target the E1 and E2 subunits to prevent viral entry [Adams et al., 2021]. Additionally, investigational vaccines often utilize these structural proteins to elicit a protective immune response [CDC, 2023]. EEEV is highly pathogenic, causing severe encephalitis with mortality rates up to 30-70%, making these structural proteins critical targets for medical countermeasures [CDC, 2023].

Other names

EEEV structural proteinsEEEV polyproteinCapsid-E3-E2-6K-E1 polyproteinEastern equine encephalitis virus envelope proteins

Neutralizing antibodies and vaccine-induced antibodies bind to specific epitopes on the E1 or E2 glycoproteins. This binding either sterically hinders the interaction between the E2 protein and host cell receptors (such as VLDLR) or prevents the E1-mediated membrane fusion process by blocking the conformational changes required for fusion at low pH [Adams et al., 2021; Hundie et al., 2022].